Inclusion Criteria:

• Histological or cytological evidence of one of the following malignancies: breast, colorectal, prostate, lung, ovarian, endometrial, bladder, salivary gland or other cancer which the Investigator and Sponsor believe may express the ErbB2 target.
• Subjects with advanced solid tumors that have failed at least one previous therapeutic regimen and either no longer are candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy.
• Subjects with ErbB2 positive breast cancer and with clinical indication for trastuzumab or lapatinib should have received prior therapy with trastuzumab and lapatinib (if available) or declined the treatment option of trastuzumab and lapatinib prior to entry into the study.
• Subject has an ECOG performance status between 0-2 (Part A) and between 0-1 (Part B)
• Measurable disease (at least 1 target lesion) according to modified RECIST (Part B Only)

Exclusion Criteria:

• Subject has uncontrolled or symptomatic brain metastases (If a subject has brain metastases and is on steroids, the steroid dose must be stable for at least 30 days).
• Use of an investigational medication or device within 30 days of initiating study therapy.
• Major surgery within 30 days prior to first dose.
• Radiotherapy or chemotherapy within 28 days prior to first dose (not including palliative radiotherapy at focal sites).
• Pregnancy or lactation.
• Known positive for HIV, Hepatitis B and/or Hepatitis C